These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
324 related articles for article (PubMed ID: 33640225)
1. The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy. Lenis AT; Fero KE; Ojeaburu L; Lec PM; Golla V; Brisbane W; Leapman MS; Chamie K Urol Oncol; 2021 Aug; 39(8):496.e17-496.e24. PubMed ID: 33640225 [TBL] [Abstract][Full Text] [Related]
2. Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy. von Landenberg N; Speed JM; Cole AP; Seisen T; Lipsitz SR; Gild P; Menon M; Kibel AS; Roghmann F; Noldus J; Sun M; Trinh QD Urol Oncol; 2018 Feb; 36(2):78.e13-78.e19. PubMed ID: 29169845 [TBL] [Abstract][Full Text] [Related]
3. A delay ≥8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging. Audenet F; Sfakianos JP; Waingankar N; Ruel NH; Galsky MD; Yuh BE; Gin GE Urol Oncol; 2019 Feb; 37(2):116-122. PubMed ID: 30509868 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study. Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141 [TBL] [Abstract][Full Text] [Related]
5. Induction Chemotherapy Followed by Surgery Versus Upfront Radical Cystectomy in Patients With Clinically Node-positive Muscle-invasive Bladder Cancer. Pak S; You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Kim CS; Ahn H Clin Genitourin Cancer; 2019 Jun; 17(3):e420-e428. PubMed ID: 30713014 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350 [TBL] [Abstract][Full Text] [Related]
7. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. Gschwend JE; Heck MM; Lehmann J; Rübben H; Albers P; Wolff JM; Frohneberg D; de Geeter P; Heidenreich A; Kälble T; Stöckle M; Schnöller T; Stenzl A; Müller M; Truss M; Roth S; Liehr UB; Leißner J; Bregenzer T; Retz M Eur Urol; 2019 Apr; 75(4):604-611. PubMed ID: 30337060 [TBL] [Abstract][Full Text] [Related]
9. The Role of Lymph Node Dissection in Patients With Muscle-Invasive Bladder Cancer Who Underwent Radical Cystectomy Following Neoadjuvant Chemotherapy. Zennami K; Takahara K; Nukaya T; Takenaka M; Ichino M; Sasaki H; Kusaka M; Sumitomo M; Shiroki R Clin Genitourin Cancer; 2024 Apr; 22(2):1-9. PubMed ID: 37423863 [TBL] [Abstract][Full Text] [Related]
10. The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group. Gild P; Vetterlein MW; Seiler R; Necchi A; Hendricksen K; Mertens LS; Roghmann F; Landenberg NV; Gontero P; Cumberbatch M; Dobruch J; Seisen T; Grande P; D'Andrea D; Anract J; Comploj E; Pycha A; Saba K; Poyet C; van Rhijn BW; Noon AP; Roupret M; Shariat SF; Fisch M; Xylinas E; Rink M Surg Oncol; 2020 Sep; 34():312-317. PubMed ID: 32891350 [TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer. Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y Med Oncol; 2014 May; 31(5):949. PubMed ID: 24700028 [TBL] [Abstract][Full Text] [Related]
12. Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience. Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ BJU Int; 2019 Jun; 123(6):1011-1019. PubMed ID: 30623554 [TBL] [Abstract][Full Text] [Related]
13. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Bhindi B; Frank I; Mason RJ; Tarrell RF; Thapa P; Cheville JC; Costello BA; Pagliaro LC; Karnes RJ; Thompson RH; Tollefson MK; Boorjian SA Eur Urol; 2017 Nov; 72(5):660-664. PubMed ID: 28545841 [TBL] [Abstract][Full Text] [Related]
14. Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy. Chalfin HJ; Liu JJ; Gandhi N; Feng Z; Johnson D; Netto GJ; Drake CG; Hahn NM; Schoenberg MP; Trock BJ; Scott AV; Frank SM; Bivalacqua TJ Ann Surg Oncol; 2016 Aug; 23(8):2715-22. PubMed ID: 27012987 [TBL] [Abstract][Full Text] [Related]
15. Determinants of adequate lymph node dissection following neoadjuvant chemotherapy in patients with urothelial muscle-invasive bladder cancer: results from the National Cancer Database. Monaghan TF; Flores VX; Suss NR; Robins DJ; Smith MT; McNeil BK; Hyacinthe LM; Weiss JP; Winer AG Int Urol Nephrol; 2021 Feb; 53(2):235-239. PubMed ID: 32865771 [TBL] [Abstract][Full Text] [Related]
16. Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer. Williams SB; Shan Y; Jazzar U; Mehta HB; Baillargeon JG; Huo J; Senagore AJ; Orihuela E; Tyler DS; Swanson TA; Kamat AM JAMA Surg; 2018 Oct; 153(10):881-889. PubMed ID: 29955780 [TBL] [Abstract][Full Text] [Related]
17. Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy. Lee EK; Herr HW; Dickstein RJ; Kassouf W; Munsell MF; Grossman HB; Dinney CP; Kamat AM BJU Int; 2012 Dec; 110(11 Pt B):E590-5. PubMed ID: 22758775 [TBL] [Abstract][Full Text] [Related]
18. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Metcalfe MJ; Ferguson JE; Li R; Xiao L; Guo CC; Czerniak BA; Siefker-Radtke A; Pretzsch SM; Navai N; McConkey DJ; Kamat AM; Campbell M; Dinney C Eur Urol Focus; 2017 Dec; 3(6):577-583. PubMed ID: 28753816 [TBL] [Abstract][Full Text] [Related]
19. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU; Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383 [TBL] [Abstract][Full Text] [Related]
20. Oncologic outcomes of neoadjuvant chemotherapy and lymph node dissection with partial cystectomy for muscle-invasive bladder cancer. Antar RM; Xu VE; Farag CM; Lucero J; Drouaud A; Sundaresan V; Gordon OF; Azari S; Wynne M; Smith AK; Whalen MJ Transl Androl Urol; 2024 Aug; 13(8):1349-1363. PubMed ID: 39280687 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]